130 related articles for article (PubMed ID: 12688354)
1. Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism.
Pepper C; Thomas A; Fegan C; Hoy T; Bentley P
Leuk Lymphoma; 2003 Feb; 44(2):337-42. PubMed ID: 12688354
[TBL] [Abstract][Full Text] [Related]
2. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Byrd JC; Shinn C; Waselenko JK; Fuchs EJ; Lehman TA; Nguyen PL; Flinn IW; Diehl LF; Sausville E; Grever MR
Blood; 1998 Nov; 92(10):3804-16. PubMed ID: 9808574
[TBL] [Abstract][Full Text] [Related]
3. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro.
Pepper C; Thomas A; Hoy T; Milligan D; Bentley P; Fegan C
Blood; 2003 Apr; 101(7):2454-60. PubMed ID: 12446453
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells.
Takada Y; Sethi G; Sung B; Aggarwal BB
Mol Pharmacol; 2008 May; 73(5):1549-57. PubMed ID: 18287248
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.
Alonso M; Tamasdan C; Miller DC; Newcomb EW
Mol Cancer Ther; 2003 Feb; 2(2):139-50. PubMed ID: 12589031
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol-induced iNOS downregulation during apoptosis of chronic lymphocytic leukemia cells is caspase-dependent.
Billard C; Menasria F; Quiney C; Faussat AM; Kolb JP
Leuk Res; 2008 May; 32(5):755-60. PubMed ID: 17981326
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia.
Billard C; Kern C; Tang R; Ajchenbaum-Cymbalista F; Kolb JP
Leukemia; 2003 Dec; 17(12):2435-43. PubMed ID: 14523476
[TBL] [Abstract][Full Text] [Related]
8. Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiation.
Pepper C; Ali K; Thomas A; Hoy T; Fegan C; Chowdary P; Kell J; Bentley P
Eur J Haematol; 2002 Oct; 69(4):227-35. PubMed ID: 12431242
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
Pepper C; Thomas A; Hoy T; Fegan C; Bentley P
Br J Haematol; 2001 Jul; 114(1):70-7. PubMed ID: 11472347
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.
Kitada S; Zapata JM; Andreeff M; Reed JC
Blood; 2000 Jul; 96(2):393-7. PubMed ID: 10887097
[TBL] [Abstract][Full Text] [Related]
12. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Chen R; Keating MJ; Gandhi V; Plunkett W
Blood; 2005 Oct; 106(7):2513-9. PubMed ID: 15972445
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
Shapiro GI; Koestner DA; Matranga CB; Rollins BJ
Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362
[TBL] [Abstract][Full Text] [Related]
15. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
16. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.
Hussain SR; Lucas DM; Johnson AJ; Lin TS; Bakaletz AP; Dang VX; Viatchenko-Karpinski S; Ruppert AS; Byrd JC; Kuppusamy P; Crouser ED; Grever MR
Blood; 2008 Mar; 111(6):3190-9. PubMed ID: 18192508
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells.
Stadheim TA; Xiao H; Eastman A
Cancer Res; 2001 Feb; 61(4):1533-40. PubMed ID: 11245462
[TBL] [Abstract][Full Text] [Related]
19. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Gao N; Dai Y; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
[TBL] [Abstract][Full Text] [Related]
20. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
Mahoney E; Lucas DM; Gupta SV; Wagner AJ; Herman SE; Smith LL; Yeh YY; Andritsos L; Jones JA; Flynn JM; Blum KA; Zhang X; Lehman A; Kong H; Gurcan M; Grever MR; Johnson AJ; Byrd JC
Blood; 2012 Aug; 120(6):1262-73. PubMed ID: 22740450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
